Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Toralizumab (IDEC-131), a humanized monoclonal antibody (mAb) directed against CD40L (CD154), consists of human gamma 1 heavy chains and human kappa light chains. Specifically targeting CD40L on T cells, it inhibits CD40 signaling, acting as an immunosuppressive agent with potential applications in systemic lupus erythematosus (SLE) research [1] [2].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry |
Description | Toralizumab (IDEC-131), a humanized monoclonal antibody (mAb) directed against CD40L (CD154), consists of human gamma 1 heavy chains and human kappa light chains. Specifically targeting CD40L on T cells, it inhibits CD40 signaling, acting as an immunosuppressive agent with potential applications in systemic lupus erythematosus (SLE) research [1] [2]. |
Molecular Weight | 148.43 (kD) |
CAS No. | 252662-47-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Toralizumab 252662-47-8 inhibitor inhibit